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Abstract
Objectives—To better understand respiratory symptoms and lung function in flavouring 
manufacturing workers.
Methods—We offered a questionnaire and lung function testing to the current workforce of a 
flavouring manufacturing facility that had transitioned away from diacetyl and towards substitutes 
in recent years. We examined symptoms, spirometric parameters and diffusing capacity 
measurements by exposure variables, including facility tenure and time spent daily in production 
areas. We used linear and logistic regression to develop final models adjusted for age and smoking 
status.
Results—A total of 367 (93%) current workers participated. Shortness of breath was twice as 
common in those with tenure ≥7 years (OR 2.0, 95% CI 1.1 to 3.6). Other chest symptoms were 
associated with time spent daily in production. Participants who spent ≥1 h daily in production 
areas had twice the odds of any spirometric abnormality (OR 2.3; 95% CI 1.1 to 5.3) and three 
times the odds of low diffusing capacity (OR 2.8; 95% CI 0.9 to 9.4) than other participants. Mean 
spirometric parameters were significantly lower in those with tenure ≥7 years and those who spent 
≥1 h daily in production. Mean diffusing capacity parameters were significantly lower in those 
with tenure ≥7 years. Differences in symptoms and lung function could not be explained by age, 
smoking status or employment at another flavouring plant.
Conclusions—Symptoms and lung function findings were consistent with undiagnosed or 
subclinical obliterative bronchiolitis and associated with workplace exposures. Further efforts to 
lower exposures to flavouring chemicals, including diacetyl substitutes, are warranted.
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Occupational exposure to the butter flavouring chemical diacetyl has been associated with 
obliterative bronchiolitis (also known as bronchiolitis obliterans) in the microwave popcorn, 
diacetyl manufacture and coffee processing industries.1–3 Laboratory animal models have 
confirmed the respiratory toxicity of diacetyl and its substitute, 2,3-pentanedione.4–6 A 
decade of investigation led to the formal proposal in 2011 of recommended exposure limits 
for diacetyl and 2,3-pentanedione in the USA.7
Far less is known about the respiratory toxicity of other diacetyl substitutes or the multitude 
of other flavouring chemicals currently in use. Two cases of obliterative bronchiolitis in 
California flavouring manufacturing workers8 prompted industry-wide state surveillance 
that identified other probable cases and abnormal declines in the forced expiratory volume in 
1 s (FEV1) on longitudinal spirometry.910 An investigation at an Indiana flavouring 
manufacturing facility found an excess of spirometric restriction cross-sectionally and 
flavouring-related abnormal declines in FEV1 longitudinally.11 The finding of spirometric 
restriction could be consistent with obliterative bronchiolitis from diacetyl12 or it could 
represent distinct pathological effects of other exposures.
To better understand the spectrum of respiratory health in flavouring manufacturing 
workers, we conducted a cross-sectional study at a large flavouring manufacturing facility 
where obliterative bronchiolitis reportedly had been diagnosed in two former workers. Since 
the facility opened in 1998, the use of diacetyl reportedly had declined and the use of 
substitutes had increased. Neither air sampling conducted by consultants to the facility in 
2008 nor our own air sampling in 2011 detected diacetyl, although we did detect 2,3-
pentanedione.13 Thus, results of recent industrial hygiene evaluations were consistent with a 
transition away from diacetyl and towards substitutes in the years prior to our study.
METHODS
Study design
The study was conducted in accordance with the NIOSH Institutional Review Board’s 
requirements for health hazard evaluations. We invited all current workers at the facility to 
give written informed consent for an interviewer-administered questionnaire, spirometry and 
measurement of diffusing capacity. The questionnaire addressed respiratory symptoms and 
diagnoses, smoking history, work history and practices, and demographic information.13 
The respiratory questions were adapted from validated survey instruments.14–16
We conducted and interpreted spirometry testing according to published guidelines using a 
dry rolling-seal spirometer.17–19 We defined obstruction as FEV1 and ratio of FEV1 to 
forced vital capacity (FVC) below their respective lower limits of normal (5th centiles) with 
a normal FVC. We defined restrictive pattern as a normal FEV1/FVC ratio with FVC below 
the lower limit of normal. We classified participants with both FEV1/FVC ratio and FVC 
below the lower limit of normal as having mixed obstructive and restrictive abnormalities. 
We considered participants to have any spirometric abnormality if they met the definition of 
obstruction, restrictive pattern or mixed pattern.
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Participants with any spirometric abnormality who did not have medical contraindications 
were administered a bronchodilator to determine reversibility using four puffs of a β-agonist 
(albuterol). We defined reversibility as an increase in FEV1 of at least 12% and 200 mL after 
bronchodilator administration.19
We measured and interpreted the diffusing capacity of the lung for carbon monoxide 
(DLCO) using the single breath technique with helium as the tracer gas following published 
guidelines.2021 We defined low diffusing capacity as DLCO below the lower limit of normal 
and low total lung capacity as alveolar volume below the lower limit of normal.
Following the survey, we mailed reports to each participant at his or her home address. The 
reports explained individual lung function test results and provided recommendations for 
follow-up of abnormalities.
Statistical methods
We defined asthma-like symptoms as current use of asthma medicine and/or one or more of 
the following symptoms in the last 12 months: wheezing or whistling in the chest, 
awakening with a feeling of chest tightness or attack of asthma.16 We defined work-related 
symptoms as those that were reported to be better away from the facility. Of note, this 
definition of ‘work-related’ is most consistent with symptoms of reversible pathologies 
related to occupational exposures, such as irritant and allergic effects; irreversible 
pathologies related to occupational exposures, such as obliterative bronchiolitis, may not 
demonstrate a temporal relationship to the workplace.
We calculated prevalence ratios and 95% CIs of symptoms, diagnoses and lung function 
abnormalities through comparisons with data obtained from the US adult population from 
NHANES III15 using indirect standardisation for race (white or black), sex, age (17–39 or 
≥40 years) and cigarette smoking status (ever/never).
To explore potential associations between health outcomes and work, we examined 
questionnaire responses and lung function test results by exposure variables using 
contingency tables and analysis of variance to compare means. When these analyses 
revealed significant associations, we developed multivariable models using linear and 
logistic regression, adjusting for current/ former/never smoking status (for all health 
outcomes) and age (for health outcomes based on questionnaire responses). Most of the 
health outcomes based on lung function test results involve predicted values that account for 
age (as well as sex, height and, for spirometry, race). For analyses of the FEV1/FVC ratio, 
which is calculated from raw (not predicted) values, we examined the effect of age in 
adjusted models. For final adjusted models, we report ORs (for categorical outcomes) or 
least squares means (for continuous outcomes), with corresponding 95% CI.
Exposure variables were defined on the basis of participants’ self-reported work histories 
and categorised as follows: facility tenure (≥7 vs <7 years), average amount of time spent 
daily in production areas (≥1 vs <1 h); use of flavouring ingredients; use of cleaning 
products; and history of work at another flavouring plant (including another facility owned 
by the same employer).
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In this paper, we present comparisons of current/non-current categories. We also examined 
comparisons of current/never, ever/never and former/never categories, which had similar 
estimates.
Statistical analyses were conducted using SAS software V.9.3 and JMP software V.10.0.1 
(SAS Institute, Inc, Cary, North Carolina, USA). We considered two-sided p≤0.05 to be 
statistically significant. We used likelihood ratio tests to determine significance.
RESULTS
A total of 367 (93%) of 393 current workers participated. All participants completed the 
questionnaire, and most had spirometry testing (n=357) and measurement of diffusing 
capacity (n=347). All spirometry tests and 325 (94%) of the diffusing capacity tests were 
interpretable and included in our analyses.
The majority of participants were male (n=231; 63%) and white (n=334; 91%). Median 
facility tenure was 7 years (mean 8; range <1–14). Median time spent daily in production 
areas was 0 h (mean 2; range 0–10); 138 (38%) reported spending ≥1 h daily in production 
areas. A total of 165 (45%) participants reported using flavouring ingredients and 211 (57%) 
reported using cleaning products. Eighty-two (22%) had worked at another flavouring plant.
Table 1 displays age and smoking status by time spent daily in production areas and tenure. 
Age was not associated with time spent daily in production areas. Participants who spent ≥1 
h daily in production areas were more likely than other participants to be current smokers. 
Participants with tenure ≥7 years were older than other participants and less likely to be 
current smokers.
The first column of table 1 also displays participants’ responses to questions on symptoms 
and diagnoses. In addition, 10 participants (3%) reported a diagnosis of chronic bronchitis 
and 2 reported a diagnosis of chronic obstructive pulmonary disease. One participant 
reported a diagnosis of bronchiolitis obliterans, but medical records were not available for 
review. No participant reported a diagnosis of emphysema, hypersensitivity pneumonitis or 
chemical pneumonitis.
Thirty (8%) participants who had spirometry testing had an abnormal result (table 2, first 
column). Bronchodilator was administered to 24 (80%) of those with abnormal spirometry. 
The majority (n=8; 67%) of participants with obstruction or a mixed pattern (which may 
represent obstruction) had a fixed abnormality; two of those with a fixed abnormality 
reported a past history of asthma and two reported current asthma. In total, 15 (5%) tested 
participants had low diffusing capacity and 24 (7%) had low total lung capacity. Most (73%) 
participants with low diffusing capacity had normal spirometry; one had obstruction, two 
had a restrictive pattern and one had a mixed pattern. Most (67%) participants with low total 
lung capacity had normal spirometry; 8 (33%) had a restrictive pattern.
Results of adjusted comparisons with the US adult population are shown in table 3. 
Participants had higher than expected prevalence of sinusitis, wheeze, usual phlegm and 
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asthma. Nasal symptoms and restrictive pattern on spirometry were less common than 
expected.
Tables 1 and 2 also display health outcomes by time spent daily in production areas and 
tenure. Participants who spent ≥1 h daily in production areas had significantly higher 
prevalence of most symptoms, any spirometric abnormality and low diffusing capacity, as 
well as significantly lower mean spirometric parameters. Participants with ≥7-year tenure 
had nearly twice the prevalence of shortness of breath of participants with shorter tenure and 
significantly lower mean spirometric and diffusing capacity parameters. Some symptoms 
were more common in participants who reported use of flavouring ingredients or use of 
cleaning products (data not shown). There were no associations between symptoms and 
history of work at another flavouring plant. Furthermore, there were no significant 
associations between lung function abnormalities or mean lung function parameters and 
other exposure variables.
Associations between categorical health outcomes and exposure variables seen in simple 
analyses were evident in adjusted regression models (table 4). Participants who spent ≥1 h 
daily in production areas had significantly higher odds of work-related breathing trouble, 
usual phlegm and any spirometric abnormality. These participants also had higher odds of 
asthma-like symptoms, usual cough and low diffusing capacity, although these associations 
did not reach statistical significance. Participants with tenure ≥7 years had significantly 
higher odds of shortness of breath. Use of flavouring ingredients was significantly 
associated with work-related nasal symptoms, work-related breathing trouble and work-
related usual cough. Use of cleaning products was significantly associated with work-related 
sinusitis and work-related nasal symptoms.
Most associations between mean pulmonary function test parameters and exposure variables 
noted in simple analyses were significant in regression models adjusted for smoking (table 
5). Both time spent daily in production areas and tenure were significantly associated with 
mean per cent predicted FEV1 and FVC. Tenure was significantly associated with lower 
mean diffusing capacity parameters. The associations with FEV1/FVC ratio were not 
significant after adjustment for smoking status and age.
DISCUSSION
In a flavouring manufacturing workforce without excess lung function abnormalities overall, 
we found consistent associations of symptoms and lung function parameters with exposure. 
Shortness of breath, a hallmark of chronic respiratory impairment, was significantly 
associated with facility tenure. The prevalence of other chest symptoms varied with time 
spent in production areas, and work-related cough was more common in those who used 
flavouring ingredients. Upper respiratory symptoms that improved away from work were 
associated with use of cleaning products. Lung function derangements, including 
spirometric abnormalities and low diffusing capacity, were more common among 
participants spending more time in production areas. Furthermore, mean lung function 
values were inversely associated with both facility tenure and time spent in production areas. 
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Associations could not be explained by age, smoking status or employment at another 
flavouring plant.
Our findings of exposure-related chest symptoms, spirometric abnormalities, diffusing 
capacity defects and total lung capacity reductions indicate risk of occupational lung disease 
in this facility. Given the reported cases of obliterative bronchiolitis in two former workers, 
the recognised toxicity of diacetyl1–4 and the evolving understanding of lung function in 
obliterative bronchiolitis,22 these observations are most consistent with undiagnosed or 
subclinical obliterative bronchiolitis in the current workforce. Indeed, earlier reports of 
obliterative bronchiolitis in flavouring-exposed workers that emphasised fixed obstruction 
on spirometry and normal diffusing capacity1223 have given way to a more nuanced picture 
that includes a range of spirometric and diffusing capacity results.1222 In one recent case 
series of biopsy-proven obliterative bronchiolitis unrelated to flavourings, a minority (5%) 
had obstruction and 60% had diffusing capacity defects.12
There are several limitations to address. First, because our evaluation was cross-sectional, it 
was not possible to demonstrate patterns of lung function change over time. To estimate 
exposure, we used exposure surrogates rather than quantitative measurements, which may 
have allowed us to make more definitive conclusions about particular flavouring chemicals 
and cleaning products. It is possible that differences between participants and non-
participants introduced bias, but the high participation rate (93%) suggests our findings are 
representative. As we relied on participants’ reports for exposure surrogates and some health 
outcomes, our results could be affected by reporting biases. However, systematic bias in 
self-report of hire date (used to calculate tenure) seems unlikely, and lung function test 
results are not subject to reporting bias. As such, the consistency we observed in the 
association between exposure and health across a variety of metrics is reassuring. Finally, 
we were made aware of two former workers who left employment due to lung disease, and it 
is possible that others may have left employment due to respiratory illness. Thus, the current 
workforce included in the survey may have been healthier than the entire cohort of people 
who had been employed at this facility.24 The absence of former workers in our survey may 
have obscured relationships between exposure and health outcomes that an evaluation of 
both current and former workers would have found. Nonetheless, even among relatively 
healthy current workers, the impact of exposure on health was evident.
NIOSH has proposed a recommended exposure level for diacetyl of 5 ppb,7 which is 
hundreds to thousands of times lower than what was measured during prior evaluations at 
other flavouring manufacturing facilities.25–27 In contrast, this facility did not have 
documented high diacetyl exposures. However, the facility reported using amounts of 
diacetyl substitutes that put it in the same potential higher health risk category as California 
flavouring manufacturing facilities that used larger amounts of diacetyl annually.10 Our 
detection of 2,3-pentanedione at a concentration of 47 ppb in a short-term sample13 is 
notable as the proposed short-term (15 min) exposure limit is 31 ppb.7 Similarly, a longer-
term sample that resulted in a concentration of 26 ppb13 is concerning as the proposed time-
weighted average exposure limit for 2,3-pentanedione is 9.3 ppb. Our measurements, 
although limited, highlight what appears to be an ongoing shift in the flavouring 
manufacturing industry away from diacetyl and towards chemically related substitutes that 
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may have comparable toxicity.5628 Until the safety of diacetyl substitutes has been 
established, these flavouring chemicals should be considered to be respiratory toxins and 
handled using the same controls in place for diacetyl.
Little is known about the respiratory toxicity of the many flavouring chemicals other than 
diacetyl and 2,3-pentanedione used at the facility. It is certainly possible that we detected 
not only a spectrum of physiological findings of one flavouring-related disease, obliterative 
bronchiolitis, but also a spectrum of flavouring-related lung diseases. In addition to 
obliterative bronchiolitis, our findings could indicate risk of emphysema (obstruction and 
low diffusing capacity) and/or interstitial lung disease (restriction and low diffusing 
capacity). Despite predominantly fixed obstruction, the reported work-related pattern of 
some symptoms also raises the possibility of occupational or work-exacerbated 
asthma.162930 Ultimately, distinguishing among these diagnoses would require additional 
evaluation, including chest imaging, bronchoprovocation testing, cardiopulmonary exercise 
testing and lung biopsy. Yet the possible occurrence of more than one exposure-related lung 
disease in this workforce and uncertainty about the chemical cause should not serve as 
barriers to prevention. Given that decline in lung function can occur rapidly and early in 
employment in flavouring-related obliterative bronchiolitis,331–33 frequent medical 
surveillance of exposed workers that includes high-quality spirometry and close attention to 
declines (even within the normal range) is warranted.7 Furthermore, in the absence of 
additional toxicological information, an emphasis on exposure reduction through enhanced 
ventilation and use of respiratory protection is prudent.
CONCLUSION
Among current flavouring manufacturing workers, some symptoms and diagnoses were 
more common than expected, while spirometric abnormalities were not in excess. 
Symptoms, lung function abnormalities and average lung function values differed by 
exposure. These differences could not be explained by age, smoking status or employment at 
another flavouring plant, suggesting that they reflect outcomes of occupational exposures at 
the facility. These findings are most consistent with undiagnosed or subclinical obliterative 
bronchiolitis in this workforce and indicate that further efforts to lower exposures to 
flavouring chemicals, including diacetyl substitutes, are warranted.
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What this paper adds
• Flavouring manufacturing workers may be exposed to the butter flavouring 
chemical diacetyl, which causes obliterative bronchiolitis, and hundreds of other 
chemicals of unknown respiratory toxicity.
• In a facility transitioning away from diacetyl to substitutes such as 2,3-
pentanedione, workers with higher flavouring chemical exposures from more 
time spent daily in production areas and/ or longer facility tenure had more 
respiratory symptoms, more lung function abnormalities and lower mean lung 
function parameters.
• Efforts to address adverse respiratory effects of flavouring manufacture that 
focus solely on diacetyl exposure reduction are unlikely to be successful. Until 
the safety of other flavouring chemicals is established, exposure reduction (such 
as through enhanced ventilation and use of respiratory protection) and medical 
surveillance are prudent.
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Table 3
Adjusted* comparisons of symptoms, self-reported diagnoses and spirometric abnormalities among 
participants to US adult population
Observed (n) Expected (n) PR 95% CI
Symptom or diagnosis N=365
 Sinusitis 172 136.0 1.3 1.1 to 1.5
 Nasal symptoms 163 207.3 0.8 0.7 to 0.9
 Shortness of breath 81 65.9 1.2 1.0 to 1.5
 Wheeze 82 58.1 1.4 1.1 to 1.8
 Usual phlegm 56 25.5 2.2 1.7 to 2.8
 Usual cough 26 28.1 0.9 0.6 to 1.4
 Asthma, ever 44 28.4 1.5 1.2 to 2.1
 Asthma, current 28 17.7 1.6 1.1 to 2.3
 Chronic bronchitis, ever 10 18.4 0.5 0.3 to 1.0
Spirometric abnormality N=355
 Obstruction 13 12.6 1.0 0.6 to 1.8
 Restrictive pattern 15 25.4 0.6 0.4 to 1.0
 Obstruction and mixed pattern 15 18.7 0.8 0.5 to 1.3
Statistically significant prevalence ratios and CIs are in bold.
*
Adjusted for race, sex, age and smoking status.
PR, prevalence ratio.
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Table 4
Results of adjusted models of relationship between symptoms and lung function abnormalities and exposure 
variables*
Health outcome Exposure variables OR (95% CI)
Symptom
 Sinusitis Use flavourings ingredients 1.5 (1.0 to 2.4)
Use cleaning products 1.3 (0.8 to 2.1)
 WR sinusitis Time in production areas 1.7 (0.8 to 3.5)
Use flavourings ingredients 1.9 (0.9 to 4.2)
Use cleaning products 3.0 (1.3 to 8.0)
 Nasal symptoms Use flavourings ingredients 1.4 (0.9 to 2.2)
Use cleaning products 1.5 (0.9 to 2.4)
 WR nasal symptoms Time in production areas 1.2 (0.6 to 2.3)
Use flavourings ingredients 2.2 (1.1 to 4.5)
Use cleaning products 2.1 (1.0 to 4.6)
 Asthma-like symptoms Time in production areas 1.5 (0.9 to 2.4)
 Shortness of breath Tenure 2.0 (1.1 to 3.6)
 WR wheeze Time in production areas 1.8 (0.7 to 5.0)
Use flavourings ingredients 2.1 (0.7 to 6.7)
Use cleaning products 2.0 (0.6 to 7.7)
 WR breathing trouble Time in production areas 2.7 (1.1 to 7.1)
Use flavourings ingredients 2.8 (1.1 to 7.7)
 Usual phlegm Time in production areas 2.2 (1.2 to 4.0)
Use flavourings ingredients 1.4 (0.7 to 2.8)
Use cleaning products 1.5 (0.7 to 3.0)
 Usual cough Time in production areas 1.9 (1.0 to 3.7)
 WR usual cough Time in production areas 1.8 (0.5 to 7.6)
Use flavourings ingredients 4.7 (1.1 to 33)
Lung function abnormality
 Any spirometric abnormality Time in production areas 2.3 (1.1 to 5.3)
 Low diffusing capacity Time in production areas 2.8 (0.9 to 9.4)
Statistically significant associations are shown in bold.
*
Each model includes the exposure variables associated with the health outcome in univariable analyses. Wheeze and breathing trouble were not 
included in this table as they were not associated with the exposure variables in univariable analyses. Models of symptoms are adjusted for age and 
smoking status. Models of lung function abnormalities are adjusted for smoking status.
WR, work related.
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Table 5
Results of adjusted models of relationship between mean lung function parameters and exposure variables*
Health outcome Exposure variables Mean (95% CI)
Spirometry (n=357)
FEV1% predicted Time in production areas
 <1 h 100.4 (98.4 to 102.3)
 ≥1 h 96.4 (94.2 to 98.7)
Tenure
 <7 years 100.6 (98.6 to 102.7)
 ≥7 years 96.2 (94.1 to 98.3)
FVC % predicted Time in production areas
 <1 h 102.8 (101.0 to 104.6)
 ≥1 h 99.0 (96.9 to 101.1)
Tenure
 <7 years 102.3 (100.4 to 104.2)
 ≥7 years 99.5 (97.6 to 101.4)
Diffusing capacity (n=325)
 Diffusing capacity % predicted Time in production areas
 <1 h 94.0 (91.8 to 96.2)
 ≥1 h 95.4 (92.9 to 97.9)
Tenure
 <7 years 97.0 (94.7 to 99.2)
 ≥7 years 92.5 (90.1 to 94.8)
 Total lung capacity % predicted Time in production areas
 <1 h 92.6 (91.2 to 94.1)
 ≥1 h 91.9 (90.2 to 93.5)
Tenure
 <7 years 93.8 (92.3 to 95.3)
 ≥7 years 90.7 (89.1 to 92.3)
Statistically significant differences are shown in bold.
*
Each health outcome model includes the exposure variable(s) associated with the lung function parameter in univariable analyses. Time spent in 
production areas was not associated with diffusing capacity parameters in univariable models, but is included in the final adjusted models for 
comparison with the spirometry models. Means are least squares means adjusted for the other exposure variable and smoking status.
FEV1, forced exploratory volume in 1s; FVC, forced vital capacity.
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